Project Details
Description
A Phase 2, Randomized, Double-blind Study to Evaluate the Efficacy and Safety of VX-561 in Subjects aged 18 Years and Older with Cystic Fibrosis
| Status | Finished |
|---|---|
| Effective start/end date | 6/1/19 → 7/31/22 |
Funding
- VERTEX PHARMACEUTICALS INCORPORATED
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.